Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 
 
Blog Home
Bob Carey
Chief Market Strategist
Click for Bio

Follow Bob on Twitter Follow Bob on LinkedIn View Videos on YouTube
 

  Biotechnology Stocks Look Cheap Relative To Past Decade
Posted Under: Sectors

 
View from the Observation Deck  
  1. From 12/31/07 through 12/29/17 (past decade), the S&P 500 Biotechnology Index posted a cumulative total return of 353.77%, compared to 184.46% for the S&P 500 Health Care Index and 126.03% for the S&P 500 Index, according to Bloomberg.
  2. Year-to-date through 3/14/18, the S&P 500 Biotechnology Index posted a total return of 7.71%, compared to 3.95% for the S&P 500 Health Care Index and 3.27% for the S&P 500 Index.
  3. The all-time closing high for the S&P 500 Biotechnology Index is 4,488.38, set on 1/29/18, according to Bloomberg. As of 3/14/18, the index stood 6.58% below its all-time closing high. 
  4. As indicated in the chart, the year-end 2018 and 2019 P/E ratio estimates for the S&P 500 Biotechnology Index were 14.88 and 13.34, respectively, as of 3/14/18, significantly below the 10-year (2008-2017) average P/E of 19.43 (not shown in chart). 
  5. As of 3/14/18, Bloomberg's consensus earnings growth rate estimates for 2018 and 2019 for the S&P 500 Biotechnology Index were 19.73% and 11.49%, respectively, according to Bloomberg. 
  6. The annual earnings (in dollars) on the S&P 500 Biotechnology Index increased from $55.25 per share in 2008 to $235.40 per share in 2017. Bloomberg's consensus estimates for 2018 and 2019 were $281.85 and $314.23 per share, respectively, as of 3/14/18. 
  7. New and potentially revolutionary drugs, such as cell and gene therapy, along with companies finding new ways to use existing drugs on larger populations, and an anticipated increase in mergers and acquisitions activity make for a healthy biotechnology market, according to Morningstar.     
This chart is for illustrative purposes only and not indicative of any actual investment. The illustration excludes the effects of taxes and brokerage commissions and other expenses incurred when investing. There can be no assurance that any of the projections cited will occur. Investors cannot invest directly in an index. The S&P 500 Biotechnology Index is a capitalization-weighted index comprised of S&P 500 constituents in the biotechnology sector. The S&P 500 Health Care Index is a capitalization-weighted index comprised of S&P 500 constituents operating in the health care sector. The S&P 500 Index is a capitalization-weighted index comprised of 500 stocks (currently 505) used to measure large-cap U.S. stock market performance.

Download a PDF of this post, please click here.

Posted on Thursday, March 15, 2018 @ 2:58 PM • Post Link Share: 
Print this post Printer Friendly

These posts were prepared by First Trust Advisors L. P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
MARKET ANALYSIS
Market Commentary and Analysis
Weekly Video
Weekly Market Commentary
Weekly Market Watch
Monthly Talking Points
Quarterly Newsletter
Market Observations
Subscribe To Receive Email
 


 PREVIOUS POSTS
This Covered Call Index Tends To Beat The Broader Market In Low And Negative Return Climates
US Stocks Ended March 9, 2018
US Economy and Credit Markets Ended March 9, 2018
Passive Investment Vehicles Have Posted The Strongest Asset Growth Since The End Of 2007
Interest Rates Policy and the Markets
U.S. Crude Oil & Natural Gas Rig Counts
US Stocks Ended March 2, 2018
US Economy and Credit Markets Ended March 2, 2018
A Snapshot of Growth vs. Value Investing
How The S&P 500 Index Has Performed Since Its 2018 Closing Low On 2/8
Archive
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial advisors are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2019 All rights reserved.